Anti-SLAMF7/CS1 Antibody (Elotuzumab)

Elotuzumab (CAS 915296-00-3) is a monoclonal antibody directed against the signaling lymphocytic activation molecule family member 7 (SLAMF7, also termed CS1), a surface receptor predominantly expressed on plasma cells, including multiple myeloma cells. Elotuzumab alone demonstrates limited direct anti-myeloma activity in relapsed or refractory multiple myeloma (RRMM). However, when administered in combination with other anti-myeloma agents, it enhances therapeutic response and improves patient outcomes. This antibody is utilized in biomedical research on plasma cell malignancies and therapeutic combination strategies.